Clinical Pharmacy Services, Pharmacy Staffing, and Adverse Drug Reactions in United States Hospitals
- 1 June 2006
- journal article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 26 (6) , 735-747
- https://doi.org/10.1592/phco.26.6.735
Abstract
Adverse drug reactions (ADRs) were examined in 1,960,059 hospitalized Medicare patients in 584 United States hospitals in 1998. A database was constructed from the MedPAR database and the National Clinical Pharmacy Services survey. The 584 hospitals were selected because they provided specific information on 14 clinical pharmacy services and on pharmacy staffing; they also had functional ADR reporting systems. The study population consisted of 35,193 Medicare patients who experienced an ADR (rate of 1.8%). Of the 14 clinical pharmacy services, 12 were associated with reduced ADR rates. The most significant reductions occurred in hospitals offering pharmacist-provided admission drug histories (odds ratio [OR] 1.864, 95% confidence interval [CI] 1.765-1.968), drug protocol management (OR 1.365, 95% CI 1.335-1.395), and ADR management (OR 1.360, 95% CI 1.328-1.392). Multivariate analysis, performed to further evaluate these findings, showed that nine variables were associated with ADR rate: pharmacist-provided in-service education (slope -0.469, p=0.018), drug information (slope -0.488, p=0.005), ADR management (slope -0.424, p=0.021), drug protocol management (slope -0.732, p=0.002), participation on the total parenteral nutrition team (slope 0.384, p=0.04), participation on the cardiopulmonary resuscitation team (slope -0.506, p=0.008), medical round participation (slope -0.422, p=0.037), admission drug histories (slope -0.712, p=0.008), and increased clinical pharmacist staffing (slope -4.345, p=0.009). As clinical pharmacist staffing increased from the 20th to the 100th percentile (from 0.93+/-0.77/100 to 5.16+/-4.11/100 occupied beds), ADRs decreased by 47.88%. In hospitals without pharmacist-provided ADR management, the following increases were noted: mean number of ADRs/100 admissions by 34.90% (OR 1.360, 95% CI 1.328-1.392), length of stay 13.64% (Mann-Whitney U test [U]=11047367, p=0.017), death rate 53.64% (OR 1.574, 95% CI 1.423-1.731), total Medicare charges 6.88% (U=111298871, p=0.018), and drug charges 8.16% (U=108979074, p<0.001). Patients in hospitals without pharmacist-provided ADR management had an excess of 4266 ADRs, 443 deaths, 85,554 patient-days, $11,745,342 in total Medicare charges, and $1,857,744 in drug charges. The implications of these findings are significant for our health care system, especially considering that the study population represented 15.55% of 12,261,737 Medicare patients and 5.71% of the 34,345,436 patients admitted to all U.S. hospitals.Keywords
This publication has 35 references indexed in Scilit:
- Clinical and economic outcomes of pharmacist-managed aminoglycoside or vancomycin therapyAmerican Journal of Health-System Pharmacy, 2005
- Postmarketing Surveillance—Lack of Vigilance, Lack of TrustJAMA, 2004
- Merck's Recall of Rofecoxib — A Strategic PerspectiveNew England Journal of Medicine, 2004
- Failing the Public Health — Rofecoxib, Merck, and the FDANew England Journal of Medicine, 2004
- Expecting the Unexpected — Drug Safety, Pharmacovigilance, and the Prepared MindNew England Journal of Medicine, 2004
- Drug-related morbidity and mortality. A cost-of-illness modelArchives of internal medicine (1960), 1995
- Impact of a clinical pharmacist in a multidisciplinary intensive care unitCritical Care Medicine, 1994
- Use of multiple regression in counseling psychology research: A flexible data-analytic strategy.Journal of Counseling Psychology, 1987
- Sustained improvement in drug documentation, compliance, and disease control. A four-year analysis of an ambulatory care modelArchives of internal medicine (1960), 1984
- Role of the clinical pharmacist in improving drug therapy. Clinical pharmacists in outpatient therapyArchives of internal medicine (1960), 1981